Is Utah Medical Products, Inc. overvalued or undervalued?

As of 29 January 2024, the valuation grade for Utah Medical Products, Inc. has moved from fair to attractive, indicating a positive shift in its valuation outlook. The company is currently deemed undervalued. Key financial ratios include a P/E ratio of 14, an EV to EBITDA of 6.29, and a remarkable ROCE of 38.15%, which highlights its efficient use of capital.
In comparison with peers, Utah Medical Products has a P/E ratio of 13.53, while Tactile Systems Technology, Inc. stands at 14.08, suggesting that Utah is competitively priced within its industry. Notably, CareDx, Inc. is classified as very attractive but has a significantly negative P/E ratio, indicating potential issues that could affect its valuation. Despite recent stock performance lagging behind the S&P 500, with a YTD return of -10.70% compared to the S&P 500's 2.44%, the company's strong fundamentals suggest it may present a buying opportunity for investors.